Skip to main content

Jeong-Mi Oh

Seoul National University · Medicine

About the Lab

Professor Jeong-Mi Oh's research lab specializes in pharmacogenomics and pharmacoepigenetics, focusing on how genetic and epigenetic variations influence individual drug response. The lab investigates epigenetic mechanisms—such as DNA methylation and histone modification—that regulate drug-metabolizing enzymes and transporters, particularly cytochrome P450 enzymes. It also develops machine learning models for quantitative prediction of pharmacokinetic drug-drug interactions, supported by a comprehensive, FDA label-derived database. Additionally, the lab explores clinical associations between chronic inflammatory conditions like atopic diseases and anemia, integrating real-world health data for population-level insights.

pharmacogenomicspharmacoepigeneticsdrug-drug interactionscytochrome P450anemia in atopy

Research Overview

Papers
236
Total Citations
5,079
Papers (5y)
46
Primary Field
Medicine

Research Output Trend

Figures are computed from collected data and may differ slightly.

Publications per year (5y)
46total
2021
2022
2023
2024
2025
Citations per year (5y)
282total
20212022202320242025

Selected Papers

15
1
Article|75 citations·2013
Epigenetic Changes in Gene Expression for Drug‐Metabolizing Enzymes and Transporters
In‐Wha Kim, Nayoung Han, Gilbert J. Burckart, Jung Mi Oh
SJR Q1Pharmacotherapy The Journal of Human Pharmacology and Drug TherapyOA

Individual differences in drug response can be caused by genetic and epigenetic variability and disease determinants. Pharmacoepigenetics is a new field that studies the expression changes in pharmacogenes without changes in DNA sequences. Epigenetic control mechanisms are associated with DNA methylation, histone modification, small noncoding RNAs, and nucleosome remodeling. Researchers are actively attempting to identify epigenetic mechanisms for controlling the expression of enzymes and transp

Molecular BiologyBiochemistry, Genetics and Molecular Biology
2
Article|73 citations·2007
Low‐Dose Botulinum Toxin Type A for the Treatment of Refractory Piriformis Syndrome
Se Jin Yoon, Jin Young Ho, Ho Yeong Kang, Sang‐Ho Lee, Kyung Im Kim, Wan Gyoon Shin, Jung Mi Oh
SJR Q1Pharmacotherapy The Journal of Human Pharmacology and Drug TherapyOA

STUDY OBJECTIVES: To evaluate the efficacy of a single, low-dose injection of botulinum toxin type A in relieving pain in Korean patients with piriformis syndrome resistant to conventional therapy, and to assess the drug's influence on these patients' quality of life. DESIGN: Prospective, single-site, open-label trial. SETTING: Rehabilitation medicine clinic in Seoul, Korea. PATIENTS: Twenty-nine patients with a confirmed diagnosis of chronic piriformis syndrome and 82 age- and sex-matched healt

Cell BiologyBiochemistry, Genetics and Molecular Biology
3
Article|73 citations·2012
Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients
Nayoung Han, Hwi‐yeol Yun, Jin-yi Hong, In‐Wha Kim, Eunhee Ji, Su Hyun Hong, Yon Su Kim, Jongwon Ha, Wan Gyoon Shin, Jung Mi Oh
SJR Q2European Journal of Clinical Pharmacology
TransplantationMedicine
4
Article|57 citations·2022
Machine learning-based quantitative prediction of drug exposure in drug-drug interactions using drug label information
Ha Young Jang, Jihyeon Song, Jae Hyun Kim, Howard Lee, In‐Wha Kim, Bongki Moon, Jung Mi Oh
SJR Q1npj Digital MedicineOA

Many machine learning techniques provide a simple prediction for drug-drug interactions (DDIs). However, a systematically constructed database with pharmacokinetic (PK) DDI information does not exist, nor is there a machine learning model that numerically predicts PK fold change (FC) with it. Therefore, we propose a PK DDI prediction (PK-DDIP) model for quantitative DDI prediction with high accuracy, while constructing a highly reliable PK-DDI database. Reliable information of 3,627 PK DDIs was

Computational Theory and MathematicsComputer Science
5
Article|46 citations·2011
Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients
In‐Wha Kim, Yoo Jin Moon, Eunhee Ji, Kyung Im Kim, Nayoung Han, Sung Ju Kim, Wan Gyoon Shin, Jongwon Ha, Jeong-Hyun Yoon, Hye Suk Lee, Jung Mi Oh
SJR Q2European Journal of Clinical PharmacologyOA
TransplantationMedicine
6
Article|46 citations·2019
Association between atopic disease and anemia in pediatrics: a cross-sectional study
Kiyon Rhew, Jung Mi Oh
SJR Q2BMC PediatricsOA

BACKGROUND: Atopic diseases, such as atopic dermatitis, allergic rhinitis, and asthma, are inflammatory diseases common in pediatric patients. This study investigated whether these inflammatory atopic diseases were associated with anemia in pediatrics. METHODS: A cross-sectional study was conducted using a pediatric dataset from the Health Insurance Review and Assessment Service (HIRA) of South Korea in 2016. Multivariable logistic regression, adjusting for demographic covariates was used for an

PhysiologyMedicine
7
Article|45 citations·2012
Combinational Effect of Intestinal and Hepatic CYP3A5 Genotypes on Tacrolimus Pharmacokinetics in Recipients of Living Donor Liver Transplantation
Eunhee Ji, Leena Choi, Kyung‐Suk Suh, Joo‐Youn Cho, Nayoung Han, Jung Mi Oh
SJR Q1Transplantation

CYP3A5 genotypes of both recipient and donor were important factors influencing pharmacokinetic variability of tacrolimus. The recipient-donor combinational genetic effect on C/D ratio changed over time after transplantation.

TransplantationMedicine
8
Article|41 citations·2020
Atopic Disease and Anemia in Korean Patients: Cross-Sectional Study with Propensity Score Analysis
Kiyon Rhew, Joshua D. Brown, Jung Mi Oh
SJR Q2International Journal of Environmental Research and Public HealthOA

Atopic disease is associated with chronic inflammation, and anemia has been reported in patients with inflammatory disorders such as rheumatoid arthritis, chronic obstructive pulmonary disease, and irritable bowel disease. The objective of this study was to determine whether atopic disease is associated with an increased risk of anemia. A cross-sectional study with propensity score weighting was conducted using a health insurance review agency claims dataset comprised of randomized patients who

DermatologyMedicine
9
Article|40 citations·2004
Pharmacokinetic Study of Mycophenolic Acid in Korean Kidney Transplant Patients
Eun Kyung Cho, Duck Jong Han, Song Cheol Kim, Gilbert J. Burckart, Raman Venkataramanan, Jung Mi Oh
SJR Q2The Journal of Clinical Pharmacology

The purpose of this study was to characterize the pharmacokinetic parameters of mycophenolic acid (MPA) in Korean kidney transplant recipients. Plasma MPA concentrations of 10 Korean kidney transplant recipients administered a lower dose of mycophenolate mofetil (MMF; 750 mg twice a day) were measured at 2 weeks of MMF therapy by high-performance liquid chromatography (HPLC). The plasma MPA concentration-time curve pattern of patients taking lower doses of MPA was consistent with previously repo

TransplantationMedicine
10
Article|37 citations·2012
ABCB1 C3435T Genetic Polymorphism on Population Pharmacokinetics of Methotrexate After Hematopoietic Stem Cell Transplantation in Korean Patients: A Prospective Analysis
In‐Wha Kim, Hwi‐yeol Yun, Boyoon Choi, Nayoung Han, Seon-Yang Park, Eun Sook Lee, Jung Mi Oh
SJR Q1Clinical Therapeutics
Public Health, Environmental and Occupational HealthMedicine
11
Article|36 citations·2018
Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers
Jae Hyun Kim, Nayoung Han, Myeong Gyu Kim, Hwi‐yeol Yun, Sunhwa Lee, Eunjin Bae, Yon Su Kim, In‐Wha Kim, Jung Mi Oh
SJR Q1Scientific ReportsOA

Abstract The objective of the study was to investigate the pharmacokinetic drug-drug interactions between tacrolimus (TAC) and mycophenolate mofetil (MMF) in healthy Korean male volunteers. Seventeen volunteers participated in a three-period, single-dose, and fixed sequence study. They sequentially received MMF, TAC, and the combination. Concentrations of TAC, mycophenolic acid (MPA), and its metabolites MPA 7-O-glucuronide and MPA acyl glucuronide were measured. The variants of CYP3A4 , CYP3A5

TransplantationMedicine
12
Article|36 citations·2021
Effectiveness of Clinical Pharmacist Service on Drug-Related Problems and Patient Outcomes for Hospitalized Patients with Chronic Kidney Disease: A Randomized Controlled Trial
Yun‐Kyoung Song, Sohyun Jeong, Nayoung Han, Heejin Na, Ha Young Jang, Minji Sohn, Yon Su Kim, Kwon Wook Joo, Kook‐Hwan Oh, Dong Ki Kim, Hajeong Lee, Jung Mi Oh
SJR Q1Journal of Clinical MedicineOA

(1) Background: The study aimed to analyze the effectiveness of clinical pharmacist services on drug-related problems (DRPs) and patient outcomes in inpatients with chronic kidney disease (CKD). (2) Methods: In a randomized controlled trial, the participants in the intervention group received pharmacist services, including medication reconciliation, medication evaluation and management, and discharge pharmaceutical care transition services. Participants in the control group received usual care.

Geriatrics and GerontologyMedicine
13
Article|35 citations·2018
Service design oriented multidisciplinary collaborative team care service model development for resolving drug related problems
Nayoung Han, Seung Hee Han, Hyuneun Chu, Jae Hyun Kim, Ki Yon Rhew, Jeong‐Hyun Yoon, Nam Kyung Je, Sandy Jeong Rhie, Eunhee Ji, Euni Lee, Yon Su Kim, Jung Mi Oh
SJR Q1PLoS ONEOA

Our goal was to help prevent drug-related morbidity and mortality by developing a collaborative multidisciplinary team care (MTC) service model using a service design framework that addressed the unmet needs and perspectives of diverse stakeholders. Our service model was based on a "4D" framework that included Discover, Define, Design, and Develop phases. In the "discover" phase, we conducted desk research and field research of stakeholders to identify the unmet needs in existing patient care se

Geriatrics and GerontologyMedicine
14
Article|32 citations·2020
Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews
Nayoung Han, Jung Mi Oh, In‐Wha Kim
SJR Q1Scientific ReportsOA

The recommended antiviral drugs available for the treatment and prevention of influenza are neuraminidase inhibitors (NAIs). The aim of this study was to evaluate age-related clinical manifestations of adverse events (AEs) related to NAIs. FAERS and WebMD data were downloaded. The available NAIs selected for the analysis were oseltamivir, peramivir, zanamivir, and laninamivir. Disproportionality was analyzed using the proportional reporting ratio (PRR), the reporting odds ratio (ROR), and the in

EpidemiologyMedicine
15
Article|32 citations·2022
The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study
Boyoon Choi, Hyun Jin Park, Yun‐Kyoung Song, Yoon-Jeong Oh, In‐Wha Kim, Jung Mi Oh
SJR Q1Arthritis Research & TherapyOA

BACKGROUND: Tumor necrosis factor (TNF) inhibitors use in patients with rheumatoid arthritis (RA) has raised safety concerns about cancer risk, but study results remain controversial. This largest nationwide study to date compared cancer risk in TNF inhibitor users to non-biologic disease-modifying anti-rheumatic drug (nbDMARD) users in Korean patients with RA. METHODS: Data on all the eligible patients diagnosed with RA between 2005 and 2016 were retrieved from the Korean National Health Inform

RheumatologyMedicine

Research Areas

PharmacologyTransplantationGeriatrics and GerontologyHematologyPublic Health, Environmental and Occupational HealthCardiology and Cardiovascular Medicine

Dive deeper into Jeong-Mi Oh's research on Nubint

Open this lab's papers in the app to read with AI, summarize, and cite in your writing.